ArticleIranian biomedical journal2026
Effect of HIF-1α and LDHA Blockade on Gene Expression of Tumor Immune Evasion in Myeloid Leukemia Cell Lines.
Article in Iranian biomedical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumor cells utilize metabolic reprogramming to obtain the energy required for rapid proliferation. In this study, we blocked two key factors, hypoxia-inducible factor 1-alpha (HIF-1α) and lactate dehydrogenase (LDHA), in the metabolic pathway in acute myeloid leukemia (AML) cell lines to evaluate their effect on the expression of genes involved in tumor evasion. Methods: Silibinin and sodium oxamate, as HIF-1α and LDHA blockers, respectively, were used to treat K-562 and HL-60 cells. The MTT assay was used to assess cell viability, and quantitative reverse transcription PCR was used to measure the mRNA expression levels of PD-L1, CD47, and CD155. Results: Both K-562 and HL-60 cells showed a significant decrease in CD47 expression. Additionally, HL-60 cells indicated a significant suppression of CD155 expression. In contrast, PD-L1 expression remained unchanged after treatment. Conclusion: Our findings suggest that blocking signaling pathways involved in metabolic reprogramming of cancer cells could be a promising approach for modulating the expression of certain immune checkpoint ligands, warranting further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.